Approaching Proof of Concept for Antigen Specific Immunotherapy in Type 1 Diabetes – Precision Therapy in HLA DR3-DQ2 Patients
- Updates from the ongoing DIAGNODE-3 phase 3 trial, (interim readout expected March, 2026)
- Review of pharmacodynamic effects of rhGAD65 treatment
- Evidence of disease-modifying benefit in Stage 3 Type 1 diabetes and strategy to guide next-phase development and future precision-medicine strategies
NEW DATA